For others, more expensive treatment such as CSII with and without ... are common in patients with problematic hypoglycemia; they may only be eligible for an islet transplant.

Tumor HI is a rare condition that results in hypoglycemia caused by either islet cell tumors (eg, insulinomas) or non-islet cell tumors (eg, hepatocellular carcinoma).

We are thrilled with FDA’s designation, which allows us to continue developing a potential universal treatment for hypoglycemia caused by all forms of HI.” The FDA's Orphan Drug Designation is ...

Rezolute, Inc. (RZLT),a late-stage biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has ...

Rezolute, Inc. RZLT announced that the FDA has granted an Orphan Drug Designation (“ODD”) to its lead pipeline candidate, ...

Autopsy at the age of six and a half months showed marked islet-cell hyperplasia of the pancreas, suggesting that hyperinsulinism was the immediate cause of the hypoglycemia. Treatment with ACTH ...

Recently, the opportunity arose to study the effects of small doses of human growth hormone in 3 patients suffering from hypoglycemia, of whom 2 had islet-cell carcinoma of the pancreas, with ...

Rezolute received an orphan-drug designation from the Food and Drug Administration for its treatment of hypoglycemia, or low blood sugar, caused by a disease in which a tumor produces too much insulin ...

Postprandial hypoglycemia is one of the main complications of bariatric surgery and can affect up to 30% of patients. Unlike ...

A study conducted by a Brazilian researcher at Harvard shows that serotonin – a hormone known for regulating mood – plays a ...

Rezolute is advancing treatments for Congenital Hyperinsulinism and Diabetic Macular Edema with RZ402. Learn why RZLT stock ...

We are thrilled with FDA’s designation, which allows us to continue developing a potential universal treatment for hypoglycemia caused by all forms of HI.” The FDA's Orphan Drug Designation is ...